Cannabis firm sues shipper
Check your travel medical
New orca rescue attempt
No bail in Ottawa killings 
Banks must say rebate 
Regulating power prices
Iran fires at attack drones 
World's largest election 
2 detained in Volkov attack 
Apple pulls apps from China
Oil and gas leases restricted
Indigo needs turnaround 
Warriors ready for Round 2
Kalamalka Bowl cancelled
Rockets live to fight on
Hilton teams up with Sia
Swift still 'can't forgive' Kim
Grimes to ‘cap the disarray’
Kelowna will take part in a large national trial in an effort to test drugs that could slow down dementia and Alzheimer's disease. The study will follow 1300 individuals over 5 years to determine if certain medications have a positive effect.
Okanagan Clinical trials are looking for individuals who are identified as being at risk for Alzheimer’s disease to participate in the study.
The company is currently conducting a study to determine the effectiveness of two investigational medications for subjects who are identified as APOE4 homozygotes. This genetic background increases an individual’s risk of developing Alzheimer’s disease.
“Memory impairment and Alzheimer’s disease are devastating conditions with very few viable treatment options,” said Dr. Paul Latimer, psychiatrist and principal investigator for Okanagan Clinical Trials. “With an aging population and numbers on the rise, it is very important to continue searching for safe and effective treatments.”
Alzheimer’s disease is the most common form of dementia and affects almost 39 million people worldwide. It is a progressive condition with no cure. Typically, it begins by affecting an individual’s short-term memory. It worsens over time and eventually leads to death. Most often, Alzheimer’s affects people over the age of 65, but some develop early-onset Alzheimer’s much earlier in life.
Eligible volunteers for this study will be men and women between the ages of 60 and 75 with no memory impairments or other symptoms of early Alzheimer’s disease.
